image
Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 134.07
-2.07 %
$ 6.58 B
Market Cap
638.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CRL stock under the worst case scenario is HIDDEN Compared to the current market price of 134 USD, Charles River Laboratories International, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CRL stock under the base case scenario is HIDDEN Compared to the current market price of 134 USD, Charles River Laboratories International, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CRL stock under the best case scenario is HIDDEN Compared to the current market price of 134 USD, Charles River Laboratories International, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CRL

image
$230.0$230.0$220.0$220.0$210.0$210.0$200.0$200.0$190.0$190.0$180.0$180.0$170.0$170.0$160.0$160.0$150.0$150.0$140.0$140.0$130.0$130.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
4.05 B REVENUE
-1.92%
227 M OPERATING INCOME
-63.17%
25.3 M NET INCOME
-94.74%
735 M OPERATING CASH FLOW
7.41%
-245 M INVESTING CASH FLOW
56.48%
-551 M FINANCING CASH FLOW
-544.20%
1 B REVENUE
-0.71%
-168 M OPERATING INCOME
-142.83%
-214 M NET INCOME
-304.07%
159 M OPERATING CASH FLOW
-36.71%
-76.1 M INVESTING CASH FLOW
-256.89%
-75.9 M FINANCING CASH FLOW
63.44%
Balance Sheet Charles River Laboratories International, Inc.
image
Current Assets 1.4 B
Cash & Short-Term Investments 195 M
Receivables 721 M
Other Current Assets 488 M
Non-Current Assets 6.13 B
Long-Term Investments 218 M
PP&E 2.02 B
Other Non-Current Assets 3.89 B
9.58 %6.48 %2.90 %26.79 %51.68 %Total Assets$7.5b
Current Liabilities 994 M
Accounts Payable 140 M
Short-Term Debt 0
Other Current Liabilities 854 M
Non-Current Liabilities 3.03 B
Long-Term Debt 2.72 B
Other Non-Current Liabilities 302 M
3.49 %21.24 %67.76 %7.52 %Total Liabilities$4.0b
EFFICIENCY
Earnings Waterfall Charles River Laboratories International, Inc.
image
Revenue 4.05 B
Cost Of Revenue 2.72 B
Gross Profit 1.33 B
Operating Expenses 1.1 B
Operating Income 227 M
Other Expenses 202 M
Net Income 25.3 M
5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(3b)1b(1b)227m(202m)25mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
32.88% GROSS MARGIN
32.88%
5.61% OPERATING MARGIN
5.61%
0.55% NET MARGIN
0.55%
0.64% ROE
0.64%
0.29% ROA
0.29%
0.95% ROIC
0.95%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Charles River Laboratories International, Inc.
image
600m600m500m500m400m400m300m300m200m200m100m100m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 25.3 M
Depreciation & Amortization 362 M
Capital Expenditures -233 M
Stock-Based Compensation 69.9 M
Change in Working Capital -30.3 M
Others 321 M
Free Cash Flow 502 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Charles River Laboratories International, Inc.
image
Wall Street analysts predict an average 1-year price target for CRL of $229 , with forecasts ranging from a low of $151 to a high of $290 .
CRL Lowest Price Target Wall Street Target
151 USD 12.63%
CRL Average Price Target Wall Street Target
229 USD 70.62%
CRL Highest Price Target Wall Street Target
290 USD 116.30%
Price
Max Price Target
Min Price Target
Average Price Target
300300280280260260240240220220200200180180160160140140120120May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Charles River Laboratories International, Inc.
image
Sold
0-3 MONTHS
715 K USD 1
3-6 MONTHS
1.65 M USD 1
6-9 MONTHS
6.6 M USD 2
9-12 MONTHS
374 K USD 2
Bought
1.25 M USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica. zacks.com - 2 weeks ago
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform WILMINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Valo Health announce the identification of an advanceable product candidate for treatment of lupus and other autoimmune diseases. businesswire.com - 3 weeks ago
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue? Charles River (CRL) reported earnings 30 days ago. What's next for the stock? zacks.com - 4 weeks ago
FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney's ongoing strategic growth plan, and will significantly bolster the Company's antibody discovery and engineering capabilities, strengthening its technology portfolio and expanding its gl. businesswire.com - 1 month ago
Deciphering Charles River (CRL) International Revenue Trends Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. zacks.com - 1 month ago
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance On Wednesday, Charles River Laboratories International Inc CRL reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million. benzinga.com - 1 month ago
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dave Windley - Jefferies Ann Hynes - Mizuho Justin Bowers - Deutsche Bank Lucas Romanski - TD Cowen Michael Ryskin - Bank of America Max Smock - William Blair Jacob Johnson - Stephens Patrick Donnelly - Citi Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded. seekingalpha.com - 1 month ago
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments. zacks.com - 1 month ago
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates Charles River Laboratories (CRL) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.50 per share. This compares to earnings of $2.46 per share a year ago. zacks.com - 1 month ago
Charles River beats quarterly estimates on stable demand for drug development services Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients. reuters.com - 1 month ago
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. zacks.com - 2 months ago
8. Profile Summary

Charles River Laboratories International, Inc. CRL

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 6.58 B
Dividend Yield 0.00%
Description Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Contact 251 Ballardvale Street, Wilmington, MA, 01887 https://www.criver.com
IPO Date June 23, 2000
Employees 18700
Officers Mr. Joseph W. LaPlume J.D. Corporate Executive Vice President of Corporate Development & Strategy Dr. Brian F. Bathgate Corporate Senior Vice President of European Safety Assessment Mr. John C. Ho Corporate Senior Vice President & Chief Strategy Officer Dr. Colin S. Dunn BVMS, Ph.D. Corporate Senior Vice President of Global Research Models & Services Ms. Shannon M. Parisotto Corporate Executive Vice President of Global Discovery & Safety Assessment Ian Jester Corporate Vice President of Global Sales Ms. Kristen M. Eisenhauer Senior Vice President & Chief Commercial Officer Ms. Kerstin S. Dolph Corporate Senior Vice President of Manufacturing Mr. James C. Foster J.D. Chairman, President & Chief Executive Officer Ms. Birgit Girshick Corporate Executive Vice President & Chief Operating Officer